Syed Zahoor Ul Mueen, MD
Nephrology · Rolla, MONPI 1790895597
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Vifor Pharma, Inc. at 51.9% of the total. That places this record below the midpoint for nephrology clinicians in MO, where the typical reported total is $723.
Across 38 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$355
- Otsuka America Pharmaceutical, Inc.$95
- AstraZeneca$88
- Fresenius USA Marketing, Inc.$37
- Akebia Therapeutics Inc$33
- Daiichi Sankyo Inc.$31
- plus $45 from 2 others
What the payments were for
- Food & beverage$683100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 20 | $355 |
| Otsuka America Pharmaceutical, Inc. | 5 | $95 |
| AstraZeneca | 5 | $88 |
| Fresenius USA Marketing, Inc. | 2 | $37 |
| Akebia Therapeutics Inc | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Vantive US Healthcare LLC | 1 | $29 |
| Amgen | 1 | $16 |
How this compares
$683 in reported general payments places this provider in the 45th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 48 | $4,849 |
| Calcitriol | 197 | $2,518 |
| Hydralazine Hcl | 84 | $627 |
| Potassium Chloride | 45 | $599 |
| Torsemide | 50 | $396 |
| Tamsulosin Hcl | 25 | $395 |
| Bumetanide | 20 | $358 |
| Furosemide | 92 | $337 |
| Allopurinol | 55 | $224 |
| Hydroxyzine Hcl | 17 | $183 |
| Losartan Potassium | 32 | $167 |
| Amlodipine Besylate | 44 | $166 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 22 | $162 |
| Lisinopril | 20 | $113 |
| Finasteride | 16 | $91 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Rolla
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Kevin MartinSt Louis$189K
- Alejandro AlvarezFlorissant$176K
- Gary SingerSaint Peters$170K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
- Tingting LiSaint Louis$130K
- Bahar BastaniSt Louis$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.